ACUR Acura Pharmaceuticals Inc

Price (delayed)

$0.48

Market cap

$31.24M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.03

Enterprise value

$31.48M

Highlights
Acura Pharmaceuticals's debt has shrunk by 95% YoY and by 46% QoQ
ACUR's EPS has plunged by 200% YoY but it is up by 40% from the previous quarter
ACUR's equity has soared by 102% YoY but it has shrunk by 65% QoQ
ACUR's quick ratio is down by 46% year-on-year and by 44% since the previous quarter
Acura Pharmaceuticals's gross profit has decreased by 45% YoY and by 6% from the previous quarter

Key stats

What are the main financial stats of ACUR
Market
Shares outstanding
65.09M
Market cap
$31.24M
Enterprise value
$31.48M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
231.43
Price to sales (P/S)
16.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.02
Earnings
Revenue
$2.25M
EBIT
-$839,000
EBITDA
-$757,000
Free cash flow
-$396,000
Per share
EPS
-$0.03
Free cash flow per share
-$0.01
Book value per share
$0
Revenue per share
$0.03
TBVPS
$0.02
Balance sheet
Total assets
$1.41M
Total liabilities
$1.27M
Debt
$324,000
Equity
$135,000
Working capital
-$135,000
Liquidity
Debt to equity
2.4
Current ratio
0.86
Quick ratio
0.64
Net debt/EBITDA
-0.31
Margins
EBITDA margin
-33.7%
Gross margin
100%
Net margin
-51.3%
Operating margin
-49.4%
Efficiency
Return on assets
-66.2%
Return on equity
N/A
Return on invested capital
-159.3%
Return on capital employed
-196.9%
Return on sales
-37.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACUR stock price

How has the Acura Pharmaceuticals stock price performed over time
Intraday
0%
1 week
9.09%
1 month
37.93%
1 year
-28.36%
YTD
-4%
QTD
21.52%

Financial performance

How have Acura Pharmaceuticals's revenue and profit performed over time
Revenue
$2.25M
Gross profit
$2.25M
Operating income
-$1.11M
Net income
-$1.15M
Gross margin
100%
Net margin
-51.3%
Acura Pharmaceuticals's net margin has shrunk by 158% YoY but it has increased by 22% QoQ
Acura Pharmaceuticals's gross profit has decreased by 45% YoY and by 6% from the previous quarter
Acura Pharmaceuticals's revenue has decreased by 45% YoY and by 6% QoQ
ACUR's net income is down by 42% year-on-year but it is up by 27% since the previous quarter

Growth

What is Acura Pharmaceuticals's growth rate over time

Valuation

What is Acura Pharmaceuticals stock price valuation
P/E
N/A
P/B
231.43
P/S
16.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.02
ACUR's EPS has plunged by 200% YoY but it is up by 40% from the previous quarter
ACUR's equity has soared by 102% YoY but it has shrunk by 65% QoQ
The stock's price to sales (P/S) is 110% more than its 5-year quarterly average of 7.7 and 86% more than its last 4 quarters average of 8.7
Acura Pharmaceuticals's revenue has decreased by 45% YoY and by 6% QoQ

Efficiency

How efficient is Acura Pharmaceuticals business performance
The company's return on invested capital has shrunk by 187% QoQ
Acura Pharmaceuticals's ROA has plunged by 90% YoY but it has increased by 18% from the previous quarter
ACUR's ROS is up by 22% from the previous quarter

Dividends

What is ACUR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACUR.

Financial health

How did Acura Pharmaceuticals financials performed over time
The total assets is 11% greater than the total liabilities
ACUR's total liabilities has plunged by 84% YoY and by 16% from the previous quarter
ACUR's quick ratio is down by 46% year-on-year and by 44% since the previous quarter
Acura Pharmaceuticals's debt is 140% higher than its equity
ACUR's equity has soared by 102% YoY but it has shrunk by 65% QoQ
Acura Pharmaceuticals's debt has shrunk by 95% YoY and by 46% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.